Peptidomimetics in cancer targeting

Area of Science:

• Biochemistry
• Medicinal Chemistry
• Oncology

Background:

• Cancer treatment faces challenges due to low therapeutic efficiency.
• Peptides are valuable for cancer vaccines and oncogenic pathway inhibition due to their size and production ease.
• Peptides exhibit limitations including short lifespan, instability, and low target binding affinity, hindering their clinical application.

Purpose of the Study:

• To provide a comprehensive review of designed peptidomimetics for cancer diagnosis and treatment.
• To highlight the advantages of peptidomimetics over traditional peptides in oncology.
• To discuss the potential of peptidomimetics in inhibiting cancer progression, including metastasis and angiogenesis.

Main Methods:

• Review of recent scientific literature on peptidomimetic design and evaluation.
• Analysis of chemical modifications applied to peptides to create peptidomimetics.
• Synthesis of information on the effectiveness of peptidomimetics against cancer cell growth, metastasis, and angiogenesis.

Main Results:

• Peptidomimetics demonstrate enhanced stability, longer lifespan, and improved binding affinity compared to native peptides.
• Numerous studies confirm the effectiveness of peptidomimetics in inhibiting key cancer processes like metastasis and angiogenesis.
• Designed peptidomimetics show significant potential for both diagnosing and treating various types of cancer.

Conclusions:

• Peptidomimetics represent a promising advancement over peptides for cancer therapy, addressing key limitations.
• Chemical modification of peptides yields agents with superior properties for combating malignant tumors.
• Further research and development of peptidomimetics are crucial for novel cancer diagnostics and therapeutics.